Preclinical biomarker discovery strategies help to identify potential therapeutic targets, assess the safety and effectiveness of new compounds, and inform the design of clinical trials. If introduced early in preclinical studies, they can play a key role in reducing the cost and time required for drug development.
Biomarkers can also help to identify subgroups of patients who are likely to respond to a particular therapy, which can inform the design of clinical trials and improve their chance of success.
Rely on our extensive experience and leverage our wide-collection of in vivo and in vitro preclinical models for:
In vitro screening is time and cost-efficient, and can provide useful information on drug target(s) and targeted pathways. Utilize it to:
• Explore/validate your drug mechanism of action (MoA)
• Identify genetic features associated with drug response on a set of cell lines/organoids
• Develop single or composite biomarkers
• Provide advice and guidance on future in vivo model selection
Fig. Example workflow of cell-based compound screening
In vivo screening using mouse models can mimic phase II clinical trials to provide accurate measurement of drug efficacy and is powerful for biomarker discovery due to its unique study designs. Utilize it to:
Comprehensive multiomics biomarker analysis allows researchers to gain a more complete understanding of the molecular changes that underlie a particular disease or during the response to certain treatment.
At Crown Bioscience, we continually invest in cutting-edge technologies, and validate and develop new assays, to provide our customers with a comprehensive range of multi-omics laboratory services.
Rely on our flexible methodologies, extensive experience, well-established and validated workflows, highly specialized bioinformatics teams, wide collection of historical data, high-quality, and fast turnaround, to empower your preclinical drug development.
Discover more about our comprehensive multiomics biomarker analysis platform:
Trust our extensive experience and powerful bioinformatics capabilities to maximize the value of your preclinical data, and de-risk your drug development through early identification of candidate biomarkers. Use our biomarker discovery services to advance your preclinical and clinical therapeutic candidates with:
Understand the relationships between genes, protein expression, molecular interactions and activity that define the fundamental components of a predictive biomarkers.
De-risk your therapeutic development through early identification of candidate biomarkers and clinical evaluation of companion diagnostics.
Identify responders, partial responders and non-responders with mouse clinical trials to help stratify patients before you enter the clinic.
Explore a proprietary genetic signature discovery and validation platform, allowing higher identification probability of response to your molecule.
Comprehensive data available in the databases